240 related articles for article (PubMed ID: 10940652)
21. Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.
Merlin JL; Bour-Dill C; Marchal S; Ramacci C; Poullain MG; Giroux B
Cytometry; 2000 Sep; 41(1):62-72. PubMed ID: 10942898
[TBL] [Abstract][Full Text] [Related]
22. The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma.
Rimsza LM; Campbell K; Dalton WS; Salmon S; Willcox G; Grogan TM
Leuk Lymphoma; 1999 Jul; 34(3-4):315-24. PubMed ID: 10439368
[TBL] [Abstract][Full Text] [Related]
23. Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: reversal of resistance by cyclosporin A and hyperthermia.
Larrivée B; Averill DA
Biochem Pharmacol; 1999 Jul; 58(2):291-302. PubMed ID: 10423171
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Buzzeo R; Enkemann S; Nimmanapalli R; Alsina M; Lichtenheld MG; Dalton WS; Beaupre DM
Clin Cancer Res; 2005 Aug; 11(16):6057-64. PubMed ID: 16115951
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
Inoue J; Otsuki T; Hirasawa A; Imoto I; Matsuo Y; Shimizu S; Taniwaki M; Inazawa J
Am J Pathol; 2004 Jul; 165(1):71-81. PubMed ID: 15215163
[TBL] [Abstract][Full Text] [Related]
26. Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines.
Kühne A; Tzvetkov MV; Hagos Y; Lage H; Burckhardt G; Brockmöller J
Biochem Pharmacol; 2009 Jul; 78(1):45-53. PubMed ID: 19447222
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional up-regulation of gamma-glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells.
Mulcahy RT; Untawale S; Gipp JJ
Mol Pharmacol; 1994 Nov; 46(5):909-14. PubMed ID: 7969079
[TBL] [Abstract][Full Text] [Related]
29. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB.
Greco C; D'Agnano I; Vitelli G; Vona R; Marino M; Mottolese M; Zuppi C; Capoluongo E; Ameglio F
Int J Immunopathol Pharmacol; 2006; 19(1):67-79. PubMed ID: 16569345
[TBL] [Abstract][Full Text] [Related]
30. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
[TBL] [Abstract][Full Text] [Related]
31. Expression of the human major vault protein LRP in acute myeloid leukemia.
Hart SM; Ganeshaguru K; Scheper RJ; Prentice HG; Hoffbrand AV; Mehta AB
Exp Hematol; 1997 Nov; 25(12):1227-32. PubMed ID: 9357965
[TBL] [Abstract][Full Text] [Related]
32. Annexin-I expression modulates drug resistance in tumor cells.
Wang Y; Serfass L; Roy MO; Wong J; Bonneau AM; Georges E
Biochem Biophys Res Commun; 2004 Feb; 314(2):565-70. PubMed ID: 14733945
[TBL] [Abstract][Full Text] [Related]
33. Proteometabolomics of Melphalan Resistance in Multiple Myeloma.
Koomen DC; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meads MB; Nguyen T; Meke L; Eschrich SA; Shain KH; Garrett TJ; Koomen JM
Methods Mol Biol; 2019; 1996():273-296. PubMed ID: 31127562
[TBL] [Abstract][Full Text] [Related]
34. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
35. Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.
Alexander D; Yamamoto T; Kato S; Kasai S
Surg Today; 1999; 29(5):401-6. PubMed ID: 10333409
[TBL] [Abstract][Full Text] [Related]
36. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
37. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells.
Meschini S; Calcabrini A; Monti E; Del Bufalo D; Stringaro A; Dolfini E; Arancia G
Int J Cancer; 2000 Sep; 87(5):615-28. PubMed ID: 10925353
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma.
Drain S; Flannely L; Drake MB; Kettle P; Orr N; Bjourson AJ; Catherwood MA; Alexander HD
Leuk Res; 2011 Nov; 35(11):1457-63. PubMed ID: 21705081
[TBL] [Abstract][Full Text] [Related]
39. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
40. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma.
Kurata M; Nakagawa Y; Yamamoto K; Suzuki K; Kitagawa M
Am J Hematol; 2008 Sep; 83(9):755-7. PubMed ID: 18615555
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
